Allergy Therapeutics plc has released an amended Form 8.5 announcement by Panmure Gordon (UK) Limited. The announcement provides key information regarding dealings by the exempt principal trader in relation to Allergy Therapeutics plc. The date of dealing was October 13, 2023. The announcement includes details of purchases, sales, cash-settled derivative transactions, stock-settled derivative transactions, and other dealings. The highest price per unit paid/received for the 0.1p ordinary shares was not disclosed, and the lowest price per unit paid/received was also not disclosed. The exempt principal trader made sales of 83,100 0.1p ordinary shares at a price of 0.014 per unit and purchases of 0.1p ordinary shares at a price of 0.01 per unit. The exempt principal trader also received 20,643,462 0.1p ordinary shares pursuant to an open offer at a price of 0.01 per unit. The announcement states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities. There are also no agreements, arrangements, or understandings relating to options or derivatives. The contact name provided for further information is Freddie Wooding, and the telephone number is +44 (0)20 7886 2969.